Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Wockhardt Acquires French Generics Firm

May 14, 2007 | A version of this story appeared in Volume 85, Issue 20

The Indian drug company Wockhardt has agreed to pay $265 million for Negma Laboratories, a French maker of generic drugs. With annual sales of about $150 million, Negma is France's fourth largest pharmaceutical firm, Wockhardt says. After integrating Negma, Wockhardt estimates that the European market will account for 60% of its sales. The Indian firm will now have four plants in Europe producing active pharmaceutical ingredients, injectable medicines, tablets, capsules, and creams. Negma is Wockhardt's third acquisition in the past year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.